Clozapine Use in Schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) Studies from 2001 to 2009
Yu‐Tao Xiang(University of Macau), Chay‐Hoon Tan(National University of Singapore), Norman Sartorius(The Geneva Association), Ee Heok Kua(National University of Singapore), Shuyu Yang(Amway (United States)), Senta Fujii(Hyogo Institute for Traumatic Stress), Tianmei Si(Peking University), Naotaka Shinfuku(Seinan Gakuin University), Helen Chiu(Department of Health), Lisa B. Dixon(Dixon University Center), Julie Kreyenbuhl(University of Maryland, Baltimore), Kang Sim(National University of Singapore), Michael Yong(Pacific Heart Institute), Chuanyue Wang(Capital Medical University), Edwin Lee(Center For Balanced Living), Yanling He(Shanghai Mental Health Center), Kok‐Yoon Chee(Hospital Kuala Lumpur), E.K. Chung(Seoul National University Hospital), Pichet Udomratn(Prince of Songkla University), Jitendra K. Trivedi, Mian‐Yoon Chong(Chang Gung University)
Cited by 43
Related Papers
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
|Schizophrenia Bulletin|2009|915
Reduced default mode network functional connectivity in patients with recurrent major depressive disorder
|Proceedings of the National Academy of Sciences|2019|865
The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements
|Schizophrenia Bulletin|2009|781
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
|Schizophrenia Bulletin|2004|768
Improving polygenic prediction in ancestrally diverse populations
|Nature Genetics|2022|714